Good news! Viatris Inc. has recently made an exciting announcement regarding its planned divestitures. These divestitures will not only assist the company in achieving its original total target of a multiple above 12x on 2022 estimated adjusted EBITDA, but they also represent a whopping $6.94 billion in total gross proceeds.
Some of the divestitures included are the Over-the-Counter (OTC) business, the Women’s Healthcare business, the Active Pharmaceutical Ingredients (API) business in India, and commercialization rights in certain non-core markets. With these divestitures, Viatris Inc. will transfer around 12 facilities and over 6,000 employees, which amounts to about 15 percent of its global workforce.
The completion of these divestitures is expected by the end of the first half of 2024, subject to regulatory approvals. This will mark the successful conclusion of all Phase 1 efforts and commitments, helping the company reach its gross leverage target of 3.0x in the first half of 2024. The net proceeds from the divestitures will primarily be used for debt paydown. Exciting times lie ahead for Viatris Inc. as it continues to make strategic moves to drive its growth and success.
Agreements on Remaining Planned Divestitures
Viatris Inc. is delighted to announce that it has reached agreements on its remaining planned divestitures. These divestitures are a crucial step for the company to achieve its original total target of a multiple above 12x on its 2022 estimated adjusted EBITDA. By strategically divesting certain businesses and assets, Viatris is ensuring its continued growth and success in the pharmaceutical industry.
Details of the Divestitures
This image is property of www.prnewswire.com.
The divestitures agreed upon by Viatris include several key business segments. Firstly, the Over-the-Counter (OTC) business will be divested, allowing the company to focus on its core pharmaceutical operations.
Additionally, the Women’s Healthcare business, while valuable, is being divested to streamline the company’s portfolio and allocate resources more efficiently. Furthermore, the Active Pharmaceutical Ingredients (API) business in India will be divested, enabling the company to optimize its operations and concentrate on other strategic priorities.
Lastly, Viatris is divesting its commercialization rights in certain non-core markets, ensuring a sharper focus on core markets and expansion opportunities.
Total Transactions Value
The total transaction value of these divestitures represents an impressive amount of up to $6.94 billion in total gross proceeds. This significant sum underscores the value and potential of the divested businesses and assets.
Viatris is confident that these proceeds will contribute to its growth and provide ample financial resources for investment in core areas.
Facilities and Employees Conveyed
This image is property of images.unsplash.com.
As a result of the divestitures, Viatris will convey several facilities and employees to the acquiring entities. Up to 12 facilities will be transferred as part of the divestitures. This action allows Viatris to optimize its operations and focus on its core competencies.
Additionally, these divestitures will impact approximately 6,000 employees, representing approximately 15 percent of the company’s global workforce. While these changes may bring about certain adjustments, Viatris is committed to ensuring a smooth transition for its employees and to supporting them throughout the process.
Expected Completion Timeline
The completion of these divestitures is expected to occur by the end of the first half of 2024. However, it is important to note that the timeline is subject to regulatory approvals.
Viatris is actively working with regulatory authorities to meet all requirements and ensure timely and successful completion. The company recognizes the importance of compliance and adherence to regulatory processes to create a transparent and ethical business environment.
Completion of Phase 1 Efforts and Commitments
This image is the property of images.unsplash.com.
With the conclusion of these divestitures, Viatris will achieve a successful conclusion to all Phase 1 efforts and commitments. This milestone is a testament to the company’s dedication and commitment to fulfilling its strategic objectives.
By divesting certain businesses and assets, Viatris is demonstrating its ability to adapt and evolve in an ever-changing pharmaceutical landscape. Furthermore, the completion of these divestitures aligns with the company’s goal of reaching its gross leverage target of 3.0x in the first half of 2024.
Use of Net Proceeds
Viatris has carefully considered the use of the net proceeds generated from these divestitures. The company’s top priority is to prioritize debt paydown, which will strengthen its financial position and reduce its leverage. By strategically reducing its debt, Viatris can further invest in research and development, innovation, and expansion opportunities, bolstering its long-term growth and sustainability.
In conclusion, Viatris Inc.’s agreements on its remaining planned divestitures are a significant achievement for the company. These divestitures enable Viatris to achieve its financial targets, optimize its operations, and focus on its core pharmaceutical business.
Additionally, the divested businesses and assets will provide substantial proceeds that will be utilized to pay down debt and support future growth initiatives. Viatris remains committed to ensuring a smooth transition for its employees and complying with regulatory requirements throughout the divestiture process.
With these divestitures, Viatris is confident in its ability to enhance its position in the pharmaceutical industry and fulfill its commitment to delivering high-quality healthcare solutions to patients worldwide.
